Applied Therapeutics to Present at the 2024 UBS Global Healthcare Conference
Rhea-AI Summary
Applied Therapeutics (Nasdaq: APLT), a clinical-stage biopharmaceutical company, has announced its participation in the 2024 UBS Global Healthcare Conference. The presentation is scheduled for Tuesday, November 12, 2024, at 7:15 a.m. PT in Rancho Palos Verdes, California.
The company will provide a live webcast of the event through their website's Investor Relations section at www.appliedtherapeutics.com. Interested parties can access the presentation recording for 90 days following the event on the company's website.
Positive
- None.
Negative
- None.
News Market Reaction – APLT
On the day this news was published, APLT gained 4.00%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present at the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024, at 7:15 a.m. PT in Rancho Palos Verdes, California.
A live webcast for this event will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at www.appliedtherapeutics.com. A replay of the webcast will be archived on the Company’s website for 90 days following the event.
About Applied Therapeutics
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
To learn more, please visit www.appliedtherapeutics.com and follow the company on Twitter @Applied_Tx.
Contacts
Investors:
Julie Seidel/Andrew Vulis
646-970-0543
appliedtherapeutics@argotpartners.com
Media:
media@appliedtherapeutics.com
FAQ
When is Applied Therapeutics (APLT) presenting at the 2024 UBS Global Healthcare Conference?
How can I watch Applied Therapeutics' (APLT) presentation at the UBS Healthcare Conference?
How long will Applied Therapeutics' (APLT) UBS Conference presentation be available for replay?
Where is Applied Therapeutics (APLT) presenting at the 2024 UBS Global Healthcare Conference?
